Research Feed

RELX PLC (RLXXF) is the sixth major data provider sold off -20% to -55% on AI disruption fears while posting strong execution. The Q4 2025 earnings call (Feb 12, 2026) shows 7% revenue growth, 9% profit growth, 35% margins, 99% cash conversion, and a GBP 2.25B buyback (+50% YoY) — management buying

Becton Dickinson closed the Reverse Morris Trust spinoff of its Life Sciences business to Waters on Feb 9 — nearly 2 months ahead of schedule. The company received $4B cash and is immediately deploying $2B into accelerated share repurchases and $2B into debt paydown, both "near term." At current pri

$800M gov-tech SaaS company at RSI 25, 30.6% short interest, trading 17x forward P/E while growing organic SaaS 24%+ for four consecutive quarters. Management exhausted a $50M buyback in 6 months and immediately authorized $60M more — buying 14% of the float at the technical trough. Just acquired a

Reddit just printed Rule of 115 while the stock trades at RSI 11. The Numbers Q4 revenue $726M (+70% YoY), beat guidance by $61M. Adj EBITDA $327M (45% margin). CapEx under $10M for the full year. $684M FCF. $2.5B cash, first-ever $1B buyback authorized. This is a capital-light advertising machine —

Lucky Strike reported Q2 FY2026 earnings Feb 4. Revenue +2.3%, but Adjusted EBITDA collapsed -21.6% ($77.5M vs $98.8M YoY). Net loss -$12.7M vs profit +$28.3M year ago. Stock cratered -17.5% on 8.6x average volume to $6.01. Market says: "Turnaround failed." The data says something else. RSI 7.6. Tha

PBH's Q3 10-Q (filed Feb 5) quantifies the cost of their Clear Eyes supply crisis: $10.3M supplier loan write-off, 22% revenue collapse in Eye & Ear Care ($92M vs $118M YTD), and a $125.5M acquisition of Pillar5 Pharma to secure manufacturing capacity. The thesis: Vertical integration turns crisis i

Qualcomm reported record Q1 FY2026 revenue ($12.25B vs $12.23B est) and beat EPS ($3.50 vs $3.41), then guided Q2 revenue below consensus ($10.2-11.0B vs $11.02B est, miss of $420M or 4%). Stock dropped 10% after-hours Feb 4, down 18% over 1 month. The beat-then-guide-down wasn't execution failure.

Disney borrowed $4.6B and repurchased $2.0B of stock while operating cash flow turned sharply negative. This capital allocation decision—levering up for buybacks during a cash burn quarter—raises questions about management discipline. The OpCF decline is worse than headline numbers suggest even afte

Varonis (VRNS) cratered -10.8% today (Feb 4) on 8.8× normal volume, closing at $23.67. RSI plunged to 17.7 — extreme oversold territory. The stock is now trading 30% below the $33.45 price where management executed $15M of buybacks just 8 weeks ago (Dec 2025). The selloff appears driven by two facto

Graphic Packaging collapsed 16% today on Q4 2025 earnings, hitting 52-week lows on 6× normal volume. RSI 18.3. Down 53% from highs. Trading at 6.09× forward earnings with a 3% dividend yield. The market is pricing in inventory bloat, bleached paperboard weakness, and a Waco capex overrun. But there'

PRXXF reported a SEK 245M operating loss in Q4 2025, but generated SEK 513M in operating cash flow (near 2-year record). The GAAP loss was driven entirely by a SEK 701M Bloodlines write-down already disclosed in November 2025. The stock sits at $16.53 (52-week low), down 8.1% over the past month fol

Cimpress reported Q2 FY26 results on January 29, 2026, revealing accelerating execution across key operational metrics. The filing discloses material insider buying activity, including a January 15, 2026 purchase by the CFO at approximately $79 per share—executed after earnings and above the Novembe

CONMED reported Q4 2025 EPS of $1.43, beating consensus of $1.32, with orthopedics revenue up 12.1% and supply chain backorders at a three-year low. Despite the operational beat, management guided 2026 EPS to $4.30-$4.45, down from $4.59, attributing the decline entirely to the GI portfolio exit ($0